As of April 24, 2021, the database of the EU Medicines Agency (EMA) registered a total of almost 354,000 "Suspected drug side effects with substances" - i.e. after vaccinations with Moderna, Pfizer / BioNTech, AstraZeneca and Janssen (Johnson & Johnson). A large majority affected the 18-64 age group, which is not broken down in detail, followed by the 65-85 year olds. The majority of those affected are women. Most suspected cases concern the vector vaccine AstraZeneca (184,833), followed by the mRNA vaccines Pfizer / BioNTech (151,306) and Moderna (17,265); in the Janssen vector vaccine there were 413 cases. The figures relate to EU single market countries (EU-27 plus Iceland, Liechtenstein, Norway) and “Rest of Europe”. At Moderna (according to database "CX-924414") and Pfizer (Tozinameran / Corminaty), those affected come mainly from the health sector and mostly from the EU internal market countries. At AstraZeneca (recently called “Vaxzevria”), only a third of the suspected cases concerned health workers - probably also because many doctors, nurses, etc. refused the vaccine after reports of blood clots. The cases originate almost equally from the EU internal market and the rest of Europe. AstraZeneca has been reviewed by the EMA for unusual blood clots and low platelets, especially in younger people. Although she attested a possible connection with the vaccination, she is convinced that the benefits outweigh the risks. Vaccination may continue, with recommendation for seniors. It should be noted here that AstraZeneca also reported 24,000 suspected cases in the 65-85 age group. In the UK, AstraZeneca is given to people aged 30 and over. Since the EMA review, Spain has only vaccinated over 65-year-olds with the vaccine; a few weeks ago, on the recommendation of the Standing Vaccination Commission (Stiko), Germany began vaccinating almost only over-60-year-olds with it. If younger people have already been vaccinated with AstraZeneca, they should be able to choose whether they want the second dose of this product or - wait for an alternative. A few days ago, three federal states, Saxony, Bavaria and Mecklenburg-Western Pomerania, ended their temporary moratorium. In Austria, however, the government of Federal Chancellor Sebastian Kurz consistently relied on the AstraZeneca vaccine; even when numerous EU countries temporarily suspended dealing with it. Janssen (AD26.COV2.S) had the lowest number of reported suspected cases: In total, only 413 and over 98% from “Rest of Europe”. The reason for this: the vaccine was conditionally approved by the EU Commission on March 11th, on the recommendation of the EMA, but was not rolled out in the internal market for a long time. Because just a month later, the EMA had to check the vaccine because of a “safety signal”: there were more “thromboembolic events” and low blood platelets. The vaccine was then temporarily put on hold. In the USA, Janssen was also examined for such side effects: at least six women between 18 and 48 had previously developed serious blood clots. One woman died, another is in critical condition. As a result, there was also a vaccination freeze there, which was only lifted a few days ago. What sets the vaccine apart from the others is that supposedly only one dose of vaccine is required to achieve the desired effect. According to a press release on March 11th - about the EU emergency approval - 43,783 people from eight countries on three continents took part in the clinical phase 3 study, a third of whom were over 60 years old. The company hoped to start delivering the vaccine to EU member states in the second half of April and has promised the EU to deliver 200 million doses in 2021, it said. In the end, they even started on April 12th - before the bickering began. After the temporary vaccination stop, the EMA gave the green light a few days ago. In any case, the reputation of the serum from the Johnson & Johnson subsidiary has suffered greatly as a result.